Benign Conditions

Benign Prostatic Hyperplasia

Bladder Cancer

Female Urology

Genitourinary Cancers

Genomic Testing

Hormone Therapy

Kidney Cancer

Challenging Anatomy

Innovative Techniques

Laser Lithotripsy

PCNL Tech & Devices

Ureteroscopy Tech & Devices

Kidney Stones

Men's Health

Next-Generation Imaging

Voiding Dysfunction

OAB and Incontinence

Pediatrics

Controveries in Urologic Cancer

Drug Therapy

Prostate Cancer

Sexual Dysfunction

UTUC

Cosmetic Surgery

Urologic Surgery

Business

Practice Management

Malpractice Consult

Health Law & Policy

Media

Case-Based Peer Perspectives

Investigator Perspectives 

Medical World News

Podcasts

Urology Medical Perspectives

UTv Videos

Peer Exchange

Special Report

Virtual Tumor Board

Insights

Medcast

Peers & Perspectives

Conferences

Conference Listing

Conference Previews 

Conference Recaps

Publications

Urology Times Journal

Editorial Advisory Board

Urologists in Cancer Care

Supplements and Featured Publications

Clinical Forums Recaps

CME/CE

Resources

Begin Your Journey: Tackling Burnout

Live Events

Interactive Tools

Job Board

Partners

Treatment Landscape Evolutions

Subscribe

Articles

Benjamin P. Saylor is associate editor of Urology Times, an Advanstar Communications publication.

“We hope our findings reassure health professionals caring for postmenopausal women with a history of stroke,” says Kimia Ghias Haddadan, MD. 

Vaginal estrogen tablets not linked with increased risk of recurrent ischemic stroke 

The presentations featured data on the drug candidate BOTRESO for BPH and LUTS, as well as on the prostate cancer prevention drug MCS-8.

Positive data on BOTRESO and MCS-8 highlight dual advances in prostate health 

Robert B. Den, MD, is the Chief Medical Officer at Alpha Tau Medical as well as an associate professor of radiation oncology, cancer biology, and urology at Thomas Jefferson University in Philadelphia, Pennsylvania.

Robert B. Den, MD, outlines the exploratory applications of the Alpha DaRT technology across the prostate and bladder cancer landscapes.

Novel alpha particle therapy holds promise in prostate, bladder cancer

The company is engaged in discussions with the FDA surrounding the initiation of a pivotal phase 3 trial of Alpha1H.

Alpha1H shows favorable safety, efficacy in phase 2/3 NMIBC trial

Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do not sell my Personnal Information

Urology Times – News & Insights for Urologists & Health Professionals

Facebook

LinkedIn

Spotlight

Peers and Perspectives

Clinical

Conference

1rem

Conference Archive

Jad Chahoud, MD, MPH, MHA, discusses the mechanism of action for zanzalintinib and walks through key design elements of the STELLAR-002 trial. 

Jad Chahoud, MD, on the phase 1b STELLAR-002 trial in ccRCC

ASCO Annual Meeting

The application for adjuvant pembrolizumab in renal cell carcinoma is supported by data from the phase 3 KEYNOTE-564 trial, which were presented at the 2021 ASCO Annual Meeting. 

FDA grants adjuvant pembrolizumab priority review in kidney cancer

ASCO Annual Meeting: Bladder Cancer and RCC

“Nivolumab, combined with standard of care trimodality therapy, appears to be promising for the treatment of grade group 5 prostate cancer," says John Michael Bryant, MD. 

Nivolumab plus SOC associated with improved FFBR in GG5 prostate cancer

ASTRO Annual Meeting

Hear from 5 experts as they recap some of the top data from this year's AUA.

5 key trial insights from AUA 2025

“We were able to develop a machine learning model that had decent accuracy…in predicting which patients would have an additional stone event and which patients wouldn't,” says Kevin Shee, MD, PhD.

Machine-learning algorithm for predicting stone recurrence shows promise

AUA Regional Meetings

“I think the one thing that we're hopeful for is that people will start to look at vitamin D as a potential chemoprevention agent,” says Adam B. Murphy, MD, MBA, MSCI.

Vitamin D deficiency is associated with prostate tumor gene expression

AUA: Prostate Cancer

“It's still relatively early, but this study in close to 1000 patients validated this algorithm, and it's now being studied prospectively as well,” says Yair Lotan, MD.

Yair Lotan, MD, on the development of an AI algorithm to predict BCG response in NMIBC

BCAN

Betty Wang, MD, provides insight on 3 presentations that she believes “may be game changing” in urology.

Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025

EAU Annual Congress 

"Both AR and neuroendocrine marker expressions in mCSPC patients at baseline is associated with worse prognosis," says Cedric Pobel, MD.

Cedric Pobel, MD: Key takeaways from PEACE-1 ancillary study

ESMO Annual Congress

The median OS was 34 months with 177Lu-PSMA-617 plus enzalutamide compared with 26 months with enzalutamide alone. 

Adding 177Lu-PSMA-617 to enzalutamide extends OS in mCRPC

GU Cancers Symposium

"There's a ton of activity in this space, and I think every 6 to 12 months, we're going to keep getting these boluses of information that's going to help us," says Gautam Jayram, MD. 

Gautam Jayram, MD, on key bladder cancer agents to keep an eye on 

LUGPA Annual Meeting

"This has been exciting from a physician-surgeon standpoint," says Helen L. Bernie, DO, MPH. 

Expert describes initial experience with AMS 700 with TENACIO Pump

SMSNA Meeting 

“It's the sustained release and constant exposure to the gemcitabine that's most likely responsible for the high efficacy rates of that we're seeing with the TAR-200 system,” says Siamak Daneshmand, MD.

Study shows proof of concept for sustained release with TAR-200

SUO Annual Meeting

Urologist Adam J. Gadzinski, MD, MS, shares how telemedicine can help improve access to urologic care.

Disparities in urologic care and how telemedicine can help mitigate them

SUO Videos

“The takeaway from that talk was that it's critically important to review drug plan options, particularly if the patient's on a high-cost drug,” says Kelly L. Stratton, MD, FACS.

2022 Society of Urologic Cancer Annual Meeting recap - SUO/YUO research highlight

SUO: Prostate Cancer 

“I think we really hit upon how we work closely together in renal cell cancer—urothelial cancers in particular,” says Joelle Hamilton, MD.

Medical oncologist Dr. Joelle Hamilton on multi-disciplinary cancer care with urology

UroGPO